Vistagen Therapeutics (VTGN) Common Equity (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Common Equity of $35.5 million for Q1 2026, down 30.24% sequentially from $50.9 million in Q4 2025, and down 49.54% YoY from $70.4 million in Q1 2025.
Vistagen Therapeutics (VTGN) Common Equity (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Common Equity for 15 years, with the latest figure at $35.5 million in Q1 2026.
- Quarterly Common Equity fell 49.54% year-over-year to $35.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.5 million (down 49.54% YoY) and the FY2026 annual result came in at $35.5 million, down 49.54% from the prior year.
- Common Equity declined to $35.5 million in Q1 2026 per VTGN's latest filing, from $50.9 million in the prior quarter.
- Over five years, Common Equity peaked at $123.3 million in Q4 2023 and troughed at $6.8 million in Q2 2023.
- A 5-year average of $59.5 million and a median of $56.8 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity sank 85.13% in 2023, then soared 1430.19% in 2024.
- Over 5 years, Common Equity stood at $20.7 million in 2022, then surged by 496.31% to $123.3 million in 2023, then plunged by 34.2% to $81.1 million in 2024, then sank by 37.23% to $50.9 million in 2025, then plunged by 30.24% to $35.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $35.5 million, $50.9 million, and $66.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 9.79 Bn |
| 10 | Vistagen Therapeutics | 10.52 Mn | 10.52 Mn | - | 24.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.52 Mn |
| Dec 31, 2025 | 50.92 Mn |
| Sep 30, 2025 | 66.34 Mn |
| Jun 30, 2025 | 56.77 Mn |
| Mar 31, 2025 | 70.39 Mn |
| Dec 31, 2024 | 81.12 Mn |
| Sep 30, 2024 | 92.97 Mn |
| Jun 30, 2024 | 104.80 Mn |
| Mar 31, 2024 | 114.29 Mn |
| Dec 31, 2023 | 123.29 Mn |
| Sep 30, 2023 | 35.65 Mn |
| Jun 30, 2023 | 6.85 Mn |
| Mar 31, 2023 | 12.08 Mn |
| Dec 31, 2022 | 20.67 Mn |
| Sep 30, 2022 | 29.61 Mn |
| Jun 30, 2022 | 46.05 Mn |
| Mar 31, 2022 | 64.72 Mn |
| Dec 31, 2021 | 79.98 Mn |
| Sep 30, 2021 | 80.66 Mn |
| Jun 30, 2021 | 85.62 Mn |